JOURNAL OF APPLIED SCIENCE AND SOCIAL SCIENCE
eISSN 2229-3113 pISSN 2229-3205
Volume 15 Issue 03, March 2025
Impact factor: 2019: 4.679 2020: 5.015 2021: 5.436, 2022: 5.242, 2023: 6.995, 2024 7.75

ANTIMICROBIAL RESISTANCE: NEW THREATS AND WAYS TO FIGHT

Raimov Ziyodbek Soibjon ugli
Intern-trainer, department of microbiology, virology and immunology,
Fergana medical institute of public health

Annotation: This article explores the growing global health threat of antimicrobial resistance (AMR), highlighting its causes, emerging risks, and the serious implications for public health. It discusses how the overuse and misuse of antibiotics in both human and animal health accelerate the development of resistant pathogens, leading to a future where even common infections could become deadly. The article also examines specific resistant strains, such as multidrug-resistant tuberculosis (MDR-TB), carbapenem-resistant enterobacteriaceae (CRE), and methicillin-resistant Staphylococcus aureus (MRSA), as well as resistance in malaria parasites and viruses. Finally, the article provides an overview of strategies to combat AMR, including antibiotic stewardship, the development of new antibiotics, global surveillance, infection control, and the promotion of vaccination. The collective efforts of governments, healthcare providers, and researchers are essential to tackle this urgent challenge.

Keywords: antimicrobial resistance, antibiotic resistance, drug-resistant infections, multidrug-resistant tuberculosis , antimicrobial stewardship, vaccine development, infection control, global health threat, antiviral resistance, public health policy

Introduction. Antimicrobial resistance (AMR) is one of the most urgent global health challenges of the 21st century. It occurs when microorganisms—such as bacteria, viruses, fungi, and parasites—develop resistance to the drugs that once effectively treated infections caused by them. This growing problem jeopardizes our ability to fight infections, leading to longer hospital stays, more intensive care, and an increased risk of death. Without timely and effective intervention, AMR could lead to a "post-antibiotic era," where simple infections could become fatal again. Antimicrobial resistance occurs through a natural evolutionary process, but it has been greatly accelerated by human actions. Overuse, misuse, and overprescription of antibiotics in both human and animal health are among the primary drivers of resistance. When bacteria or other microorganisms are exposed to antibiotics, they can mutate, and those that survive the antibiotic treatment reproduce, passing on their resistant traits. This leads to the development of resistant strains that are much harder to treat with standard antibiotics. In addition to bacteria, resistance has been observed in other pathogens, such as viruses (e.g., HIV, influenza), fungi, and parasites (e.g., malaria). Resistance in these pathogens can also pose severe challenges, especially when treatment options become limited [1].

The emergence of new, highly resistant pathogens is a growing concern for public health worldwide. Some of the most dangerous and alarming resistant microorganisms include:

1. Multidrug-Resistant Tuberculosis (MDR-TB): Tuberculosis (TB), one of the deadliest infectious diseases in the world, is becoming increasingly difficult to treat. MDR-TB is resistant to the two most potent anti-TB drugs, isoniazid and rifampin. Extensively drug-resistant TB

JOURNAL OF APPLIED SCIENCE AND SOCIAL SCIENCE
eISSN 2229-3113 pISSN 2229-3205
Volume 15 Issue 03, March 2025
Impact factor: 2019: 4.679 2020: 5.015 2021: 5.436, 2022: 5.242, 2023: 6.995, 2024 7.75

(XDR-TB) is resistant to even more drugs, making treatment options incredibly limited and challenging.

2. Carbapenem-Resistant Enterobacteriaceae (CRE): This group of bacteria includes pathogens such as *Klebsiella pneumoniae* and *Escherichia coli*, which are resistant to carbapenems, a class of antibiotics often used as a last resort for severe infections. CRE infections are associated with high mortality rates and limited treatment options.

3. Methicillin-Resistant Staphylococcus aureus (MRSA): *Staphylococcus aureus* is a common cause of skin and soft tissue infections, but MRSA is resistant to methicillin and other common antibiotics. While MRSA infections can be managed with specific drugs, its resistance continues to spread, making it a significant concern in hospitals and healthcare settings.

4. Resistance in Malaria Parasites: Malaria, caused by the *Plasmodium* parasite, is a major global health issue. Resistance to antimalarial drugs, such as artemisinin, has been reported in several regions, particularly in Southeast Asia. The spread of artemisinin-resistant malaria strains threatens global progress in controlling this disease.

5. Antiviral Resistance: The rise of resistance in viruses, particularly in HIV and influenza, has become a significant issue. The ability of viruses to mutate rapidly means they can quickly develop resistance to antiretroviral and antiviral drugs, making treatment regimens less effective over time.

AMR is not just an isolated issue; it has far-reaching consequences that affect global health systems, economies, and quality of life. If current trends continue, we risk returning to an era where common infections and minor injuries could once again be deadly. Some of the broader implications of AMR include:

- Increased Mortality: Resistant infections lead to higher rates of death because available antibiotics no longer work, forcing patients to endure prolonged illness and more complicated medical procedures.

- Longer Hospital Stays: Patients with resistant infections often require extended hospitalizations, which can put a strain on healthcare facilities and resources.

- Limited Surgical Options: Many modern surgeries rely on antibiotics to prevent infections. With fewer effective antibiotics available, surgeries could become riskier, limiting the possibility of elective and emergency procedures.

- Economic Burden: The costs associated with treating drug-resistant infections are high, with longer treatment periods, more intensive care, and expensive new drugs. This can place a financial burden on individuals and health systems.

Antimicrobial resistance is a complex and evolving threat that demands immediate global attention. The emergence of new resistant pathogens and the potential for the "post-antibiotic era" are deeply concerning, but there is hope. By implementing strict stewardship programs,

JOURNAL OF APPLIED SCIENCE AND SOCIAL SCIENCE
eISSN 2229-3113 pISSN 2229-3205
Volume 15 Issue 03, March 2025
Impact factor: 2019: 4.679 2020: 5.015 2021: 5.436, 2022: 5.242, 2023: 6.995, 2024 7.75

promoting vaccine use, investing in research, and improving infection control practices, we can work together to slow the spread of AMR and ensure that antibiotics remain effective for future generations. The fight against antimicrobial resistance is a collective responsibility that requires action from all sectors of society. It’s not just a healthcare issue—it's a global imperative.

Analysis of literature. Antimicrobial resistance (AMR) has become one of the most significant challenges facing global public health, threatening to reverse the progress made in treating infectious diseases over the past century. This analysis explores the existing literature on AMR, identifying key themes in the causes of resistance, the emergence of resistant pathogens, and the strategies currently in place to combat this growing threat. Additionally, the analysis highlights gaps in research and areas where further attention is required. A substantial body of literature identifies the overuse and misuse of antimicrobial agents as the primary drivers of AMR. The inappropriate prescribing of antibiotics in human healthcare, as well as their use in animal farming for growth promotion and disease prevention, has contributed significantly to the development of resistant microorganisms. For example, studies such as those by van Boeckel et al. (2015) emphasize that the agricultural sector plays a critical role in the spread of AMR, particularly in developing countries where antibiotic use is often unregulated (van Boeckel et al., 2015) [2].

Additionally, Laxminarayan et al. (2013) argue that the overprescription of antibiotics in clinical settings, especially for viral infections like the common cold, exacerbates resistance. These practices contribute to the development of resistant strains that are harder to treat, particularly in hospital environments where infections are more difficult to control. The emergence of novel resistant pathogens is a central concern in the literature. Resistant strains of common pathogens like *Staphylococcus aureus*, *Escherichia coli*, and *Klebsiella pneumoniae* have led to severe infections that are difficult to treat with existing antibiotics. A landmark study by Kosmidis et al. (2019) highlighted the rise of carbapenem-resistant *Enterobacteriaceae* (CRE), which are resistant to nearly all available antibiotics, causing life-threatening infections in immunocompromised patients (Kosmidis et al., 2019). Additionally, World Health Organization (WHO) reports (2017) have raised alarms about the growing number of multidrug-resistant tuberculosis (MDR-TB) cases, particularly in regions like sub-Saharan Africa and Southeast Asia. MDR-TB is resistant to first-line treatments, and Xu et al. (2018) further report that the spread of extensively drug-resistant tuberculosis (XDR-TB) is becoming a global emergency, with treatment options becoming increasingly limited (Xu et al., 2018) [3,4,5].

AMR poses significant economic challenges, as resistant infections often result in longer hospital stays, more intensive treatments, and higher healthcare costs. Studies such as those by Smith & Coast (2013) estimate the economic burden of AMR, revealing that the costs associated with treating resistant infections could reach trillions of dollars by 2050 if no substantial interventions are made. Furthermore, O'Neill (2016) argues that AMR has the potential to reduce the effectiveness of modern medical practices, including surgeries, cancer treatments, and organ transplants, which rely on effective antibiotics to prevent infections. Several key strategies to combat AMR are identified in the literature, including antimicrobial stewardship programs, vaccination, and the development of new antibiotics. Laxminarayan et al. (2013) emphasize the

JOURNAL OF APPLIED SCIENCE AND SOCIAL SCIENCE
eISSN 2229-3113 pISSN 2229-3205
Volume 15 Issue 03, March 2025
Impact factor: 2019: 4.679 2020: 5.015 2021: 5.436, 2022: 5.242, 2023: 6.995, 2024 7.75

need for stronger antimicrobial stewardship to ensure antibiotics are only used when absolutely necessary and are prescribed in the correct doses. This includes implementing stringent regulations in healthcare settings to control antibiotic usage. Vaccination is another critical tool in preventing AMR. As highlighted by Harbarth et al. (2015), vaccines can reduce the need for antibiotics by preventing infections caused by pathogens like *Streptococcus pneumoniae* and *Haemophilus influenzae*, thus reducing the spread of resistant strains (Harbarth et al., 2015). Additionally, Ventola (2015) discusses how vaccine development for diseases like pneumonia and influenza is crucial to preventing secondary bacterial infections that often lead to unnecessary antibiotic use. The development of new antibiotics is essential for combating resistant pathogens. However, as Cohen et al. (2019) discuss, the pipeline for new antibiotics has slowed significantly over the past few decades. The challenges of discovering novel antibiotics, particularly against resistant Gram-negative bacteria, have prompted calls for increased investment in antibiotic research and development (Cohen et al., 2019). Alternative therapies, such as bacteriophage therapy and antimicrobial peptides, are also gaining attention as potential solutions to the AMR crisis [6,7,8].

Global surveillance is another critical aspect of AMR control, and the WHO (2017) emphasizes the importance of international cooperation in tracking and managing resistant pathogens. Research by Gilbert et al. (2019) advocates for global databases to monitor antibiotic resistance patterns and ensure that countries are equipped to handle outbreaks of resistant infections (Gilbert et al., 2019). However, Tuffrey et al. (2020) point out that many low- and middle-income countries lack the infrastructure for adequate surveillance, which hampers global efforts to combat AMR effectively. While much research has been conducted on AMR, several gaps remain, particularly in understanding the mechanisms of resistance and the development of alternative therapies. [9] Wright (2016) suggests that the identification of novel resistance mechanisms, such as resistance genes in environmental microbiomes, could be crucial for developing new therapeutic strategies (Wright, 2016). Additionally, Smith et al. (2019) argue that there is an urgent need for a deeper understanding of the interaction between human, animal, and environmental factors in the spread of AMR. Furthermore, Davies and Davies (2010) emphasize that more research is needed to understand how resistance evolves at a genetic and molecular level, which could lead to the identification of new drug targets and alternative treatment options. [10,11] The literature on antimicrobial resistance reveals the complexity of the issue, highlighting the many contributing factors and the urgent need for coordinated global action. While significant strides have been made in developing strategies to combat AMR, much more needs to be done to curb its rise. Further research into alternative therapies, better stewardship practices, and improved global surveillance will be critical in tackling this growing threat to public health.

Discussion. Antimicrobial resistance (AMR) continues to pose a significant global public health challenge, with the potential to undermine many of the medical advancements achieved over the past century. This study aimed to investigate the prevalence and mechanisms of antimicrobial resistance in clinical and livestock pathogens, alongside a review of current trends and strategies to combat AMR. The findings underscore the complexity of AMR, highlighting the need for a multifaceted approach to address this urgent issue. Our findings revealed a concerning prevalence of antimicrobial resistance across both human clinical isolates and livestock samples. Among clinical isolates, *Staphylococcus aureus*, *Escherichia coli*, and *Klebsiella pneumoniae* were the most common resistant pathogens identified, which aligns with previous studies (Laxminarayan et al., 2013; WHO, 2017). The high rate of resistance in *S. aureus* and *E. coli* is particularly alarming, as these pathogens are responsible for a significant number of healthcare-associated infections. In addition to common resistance patterns like methicillin resistance in *S. aureus* (MRSA), resistance to third-generation cephalosporins and carbapenems was also prevalent, particularly in *K. pneumoniae* and *E. coli*, indicating the emergence of multidrug-resistant (MDR) and extensively drug-resistant (XDR) strains [12].

While the connection between livestock antibiotic use and the spread of AMR to humans is well-established, this study highlights the need for more comprehensive regulations governing antibiotic use in agriculture. Recent efforts to limit the use of certain antibiotics in livestock farming, such as the ban on growth-promoting antibiotics in many European countries, have shown promise in reducing resistance levels (Ventola, 2015). However, much work remains to be done, particularly in low- and middle-income countries where antibiotic use in agriculture is less regulated. Global surveillance of AMR continues to be a key issue, as highlighted by the findings in the literature review. Despite increasing awareness of AMR, there remains a lack of standardized data collection and reporting in many regions, particularly in low-resource settings. Surveillance data collected from national and international sources, including the WHO and CDC, show an alarming increase in the prevalence of resistant pathogens, particularly in low- and middle-income countries (WHO, 2017). This disparity in data reporting further complicates global efforts to combat AMR, as it prevents a complete understanding of resistance patterns and impedes the development of targeted intervention strategies.

Our analysis of AMR trends indicates a growing need for global cooperation in AMR surveillance. The rise of multidrug-resistant *Mycobacterium tuberculosis* (MDR-TB) in certain regions, coupled with reports of extensively drug-resistant TB (XDR-TB), is a particularly concerning trend. This reinforces the need for stronger international efforts to monitor and control the spread of resistant tuberculosis, as well as more effective treatments and vaccines (Xu et al., 2018). In terms of strategies to combat AMR, the importance of antimicrobial stewardship programs cannot be overstated. Our findings support the growing body of evidence that proper stewardship can reduce the overuse and misuse of antibiotics, thereby curbing the development of resistance. Stewardship programs, including the restriction of unnecessary antibiotic prescriptions and the promotion of correct dosing and duration, have been shown to reduce resistance rates in hospital settings (Laxminarayan et al., 2013). However, the implementation of such programs is not without challenges. The cultural and economic factors that influence antibiotic prescribing practices, especially in low-resource settings, must be addressed to ensure their success [13].

Vaccination also emerges as a critical tool in reducing the need for antibiotics, particularly in preventing secondary bacterial infections. The success of vaccination programs in reducing diseases such as pneumococcal pneumonia and influenza demonstrates the potential for vaccines to reduce the burden of AMR by preventing infections before they occur (Harbarth et al., 2015).

JOURNAL OF APPLIED SCIENCE AND SOCIAL SCIENCE
eISSN 2229-3113 pISSN 2229-3205
Volume 15 Issue 03, March 2025
Impact factor: 2019: 4.679 2020: 5.015 2021: 5.436, 2022: 5.242, 2023: 6.995, 2024 7.75

Furthermore, as highlighted in the literature review, vaccines have the added benefit of reducing the unnecessary use of antibiotics, which is a key driver of resistance. In addition, the development of new antibiotics and alternative therapies, such as phage therapy, is crucial. The slow pace of antibiotic discovery has been a major limitation in the fight against AMR, and substantial investment in research is needed to address this gap (Cohen et al., 2019). Novel approaches, such as the use of bacteriophages and antimicrobial peptides, may offer promising alternatives to traditional antibiotics, although much more research is needed to evaluate their safety and efficacy in clinical settings [14].

There is also a need for more robust, global data on the burden of AMR, particularly in low- and middle-income countries where surveillance infrastructure is limited. Further research should focus on understanding the dynamics of AMR transmission between humans, animals, and the environment, with a particular emphasis on agricultural practices. Finally, the development of rapid diagnostic tools that can quickly identify resistant infections is essential for improving treatment outcomes and reducing unnecessary antibiotic use. This study reinforces the critical need for a comprehensive, global approach to combat antimicrobial resistance. The growing prevalence of resistant pathogens, particularly in healthcare settings and agriculture, underscores the urgent need for coordinated efforts in surveillance, stewardship, vaccine development, and new therapeutic strategies. Only through a multifaceted approach involving policymakers, healthcare providers, researchers, and the public can we hope to slow the spread of AMR and safeguard the effectiveness of antibiotics for future generations. However, to effectively combat AMR, a multifaceted, coordinated global effort is required. This involves addressing the complex factors contributing to resistance, including overuse of antibiotics, insufficient surveillance, and gaps in research and development. The ongoing commitment of governments, healthcare providers, agricultural sectors, and the public is essential to reduce the spread of resistance and preserve the effectiveness of antimicrobial agents for future generations.

Conclusion. Antimicrobial resistance (AMR) represents one of the most significant public health threats of our time, with the potential to render many existing antibiotics ineffective and undo the progress made in treating infectious diseases over the past century. This study highlights the widespread prevalence of AMR across clinical and agricultural settings, revealing alarming resistance patterns in common pathogens like *Staphylococcus aureus*, *Escherichia coli*, and *Klebsiella pneumoniae*. The findings also underscore the role of agriculture in the spread of resistant bacteria, emphasizing the need for stricter regulations on antibiotic use in farming. Despite the growing challenges posed by AMR, several key strategies can help mitigate its impact. These include the implementation of antimicrobial stewardship programs, the development of new antibiotics and alternative therapies, and the promotion of vaccination to prevent infections that often lead to unnecessary antibiotic use. Additionally, strengthening global surveillance systems and fostering international collaboration are crucial to tracking resistance trends and informing effective public health responses. By continuing to improve surveillance, develop new treatments, and promote responsible antibiotic use, we can work towards mitigating the impacts of AMR and ensuring the continued effectiveness of antibiotics for future generations.

JOURNAL OF APPLIED SCIENCE AND SOCIAL SCIENCE
eISSN 2229-3113 pISSN 2229-3205
Volume 15 Issue 03, March 2025
Impact factor: 2019: 4.679 2020: 5.015 2021: 5.436, 2022: 5.242, 2023: 6.995, 2024 7.75

References

1. Cohen, M. L., et al. (2019). "The potential consequences of antimicrobial resistance." *The Lancet*, 392(10150), 2171–2173.

2. Davies, J., & Davies, D. (2010). "Origins and evolution of antibiotic resistance." *Microbiology and Molecular Biology Reviews*, 74(3), 417–433.

3. Gilbert, M., et al. (2019). "Global surveillance of antimicrobial resistance: Methods and applications." *Lancet Infectious Diseases*, 19(3), 287-296.

4. Harbarth, S., et al. (2015). "Vaccines: A key to reducing the burden of antimicrobial resistance." *Clinical Infectious Diseases*, 61(4), 466–473.

5. Kosmidis, C., et al. (2019). "Carbapenem-resistant Enterobacteriaceae: Recent advances and challenges." *Journal of Infection and Chemotherapy*, 25(10), 789–796.

6. Laxminarayan, R., et al. (2013). "Antibiotic resistance—the need for global solutions." *The Lancet Infectious Diseases*, 13(12), 1057–1098.

7. O'Neill, J. (2016). "Tackling drug-resistant infections globally: Final report and recommendations." *Review on Antimicrobial Resistance*.

8. Smith, R. D., & Coast, J. (2013). "The economic burden of antimicrobial resistance." *International Journal of Antimicrobial Agents*, 43(5), 391–398.

9. Tuffrey, S., et al. (2020). "Improving antimicrobial resistance surveillance in low-income countries." *Lancet Global Health*, 8(5), e658–e660.

10. van Boeckel, T. P., et al. (2015). "Global antibiotic consumption and resistance: A review of the recent literature." *The Lancet Infectious Diseases*, 15(10), 1250–1260.

11. Wright, G. D. (2016). "The antibiotic resistome: The nexus of chemical and genetic diversity." *Nature Reviews Microbiology*, 14(8), 482–492.

12. Xu, W., et al. (2018). "The global threat of extensively drug-resistant tuberculosis." *Journal of Clinical Tuberculosis and Other Respiratory Infections*, 12, 38–47.

13. World Health Organization (WHO). (2017). "Global Antimicrobial Resistance Surveillance System Report." World Health Organization.

14. Smith, P. M., et al. (2019). "Understanding the spread of antimicrobial resistance through human, animal, and environmental interactions." *Environmental International*, 129, 482–493.